drugset

drugset / Trial / NCT02218125

A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

NCT02218125 ↗

Phase 1 Completed 25 enrolled Crucell Holland BV Beth Israel Deaconess Medical Center · collab National Institute of Allergy and Infectious Diseases (NIAID) · collab US Military HIV Research Program · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.

Timeline

Start: 2014-09-23
Primary completion: 2015-11-30
Completion: 2015-11-30

Publications

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MVA-Mosaic	Vaccine	0.5 ml	Intramuscular
Subject	MVA-Mosaic	Vaccine	1e+08 unknown	Intramuscular

Indications

No indication recorded.